Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19414675 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: rituximab;   Biological: sargramostim

Indicates status has not been verified in more than two years